Three Way Crossover Closed Loop Study With Xeris Glucagon

计划入组 23 人 · 首次发布于 2018 年 2 月 6 日

Blincyto Amgen Acrotech BioPharma PH2 Blincyto Marqibo R/R Philadelphi CD19+ ALL

首次发布于 2020 年 6 月 26 日

Equivalence of A Stable Liquid Glucagon Formulation With Freshly Reconstituted Lyophilized Glucagon

计划入组 20 人 · 首次发布于 2013 年 12 月 23 日

uRAI

DEP remdesivir (Starpharma Holdings)

Polyomavirus vaccine (BioE Holdings)

LYVGEN BIOPHARMA HOLDINGS LIMITED

Cayman Islands

XERIS PHARMACEUTICALS INC

United States

XERIS PHARMACEUTICALS, INC.

United States

Xeris Biopharma Files Patent Infringement Lawsuit to Protect Recorlev Against Generic Competition

Xeris Biopharma Appoints Dr. Anh Nguyen as Chief Medical Officer to Lead Product Development Strategy

Xeris Secures Additional Orange Book Patent Protection for Recorlev Through 2040